RARE logo

Ultragenyx Pharmaceutical Inc. (RARE)

Profile

Full Name

Ultragenyx Pharmaceutical Inc.

Ticker

NASDAQ: RARE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

January 31, 2014

Indexes

Not included

Website

https://www.ultragenyx.com

Employees

1294

Key Details

Price

$29.00(-4.32%)

Market cap

$2.79B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$560.23M(+29.01% YoY)

Annual EPS

-$6.29(+23.76% YoY)

PE ratio

-

Next earnings date

Nov 6, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $29.00
    RARE price is $29.00

    30-Day Relative Volume

    1.28
    RARE 30-day relative volume is 1.28

    Price Performance

    Price Most recent change

    -4.32%
    RARE price was down -4.32% on Sep 15, 2025

    Price YTD change

    -31.07%
    RARE price is down -31.07% since January 1st

    Price 1-year change

    -50.63%
    RARE price is down -50.63% year-on-year

    Price 3-year change

    -38.66%
    RARE price is down -38.66% over the past 3 years

    Price Range

    Price All-time high

    $179.65
    RARE price is currently -83.86% below its historical high of $179.65

    Price 3-year low

    $25.81
    RARE price is currently +12.36% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $2.79B
    RARE market capitalization is $2.79 billion

    Market cap 3-year change

    -15.6%
    RARE market capitalization is down -15.6% over the past 3 years

    Market cap All-time high

    $11.74B
    RARE market capitalization is currently -76.19% below its historical high of $11.74 billion

    Market cap sector rank

    84.56%
    RARE market capitalization is higher than 84.56% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +4.56%
    RARE shares outstanding is up +4.56% year-on-year

    Shares Outstanding 3-Year Change

    +37.6%
    RARE shares outstanding is up +37.6% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    0.88
    RARE beta is 0.88

    200-day SMA

    $37.40
    RARE price is currently -22.46% below its 200-day simple moving average

    50-day SMA

    $29.69
    RARE price is currently -2.31% below its 50-day simple moving average

    RSI

    40.57
    RARE 14-day relative strength index is 40.57

    Volume

    1.28
    RARE 30-day relative volume is 1.28

    ATR

    $1.06
    RARE average true range is $1.06

    10-day Historical Volatility

    47.83%
    RARE 10-day historical volatility is 47.83%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $560.23M
    RARE annual revenue is $560.23 million

    Revenue Analysts estimate

    $657.76M
    RARE annual revenue is currently -14.83% lower than the consensus analysts' forecast

    Revenue 1-year change

    +29.01%
    RARE annual revenue is up +29.01% year-on-year

    Revenue Sector rank

    81.61%
    RARE annual revenue is higher than 81.61% of companies in Healthcare sector

    EPS

    EPS

    -$6.29
    RARE annual earnings per share is -$6.29

    EPS Analysts estimate

    -$5.06
    RARE annual earnings per share is currently +24.35% higher than the consensus analysts' forecast

    EPS 1-year change

    +23.76%
    RARE annual earnings per share is up +23.76% year-on-year

    EPS Sector rank

    16.88%
    RARE annual earnings per share is higher than 16.88% of companies in Healthcare sector

    Profit

    Gross profit

    $453.46M
    RARE annual gross profit is $453.46 million

    Gross margin

    80.94%
    RARE annual gross profit margin is 80.94%

    Operating profit

    -$535.97M
    RARE annual operating income is -$535.97 million

    Operating margin

    -95.67%
    RARE annual operating profit margin is -95.67%

    Net income

    -$569.18M
    RARE annual net profit is -$569.18 million

    Net margin

    -101.60%
    RARE annual net profit margin is -101.60%

    Expenses

    Total expenses

    $1.10B
    RARE annual total expenses is $1.10 billion

    Operating expenses

    $1.02B
    RARE annual total operating expenses is $1.02 billion

    Cost of goods sold

    $106.77M
    RARE annual cost of goods sold is $106.77 million

    Selling, general & administrative expenses

    $321.61M
    RARE annual SGA is $321.61 million

    Depreciation and amortization

    $35.54M
    RARE annual depreciation & amortization is $35.54 million

    Interest expense

    $0.00
    RARE annual interest expense is $0.00

    Income tax

    $1.60M
    RARE annual income tax is $1.60 million

    EBIT & EBITDA

    EBIT

    -$504.55M
    RARE annual earnings before interest & taxes is -$504.55 million

    EBITDA

    -$504.55M
    RARE annual EBITDA is -$504.55 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $1.50B
    RARE annual total assets is $1.50 billion

    Non current assets

    $686.33M
    RARE annual long term assets is $686.33 million

    Current assets

    $745.03M
    RARE annual total current assets is $745.03 million

    Cash and cash equivalents

    $173.73M
    RARE annual cash & cash equivalents is $173.73 million

    Accounts receivable

    $121.80M
    RARE annual accounts receivable is $121.80 million

    Inventory

    $45.01M
    RARE annual inventory is $45.01 million

    Liabilities

    Total liabilities

    $1.24B
    RARE annual total liabilities is $1.24 billion

    Long term liabilities

    $897.01M
    RARE annual total long term liabilities is $897.01 million

    Current liabilities

    $344.15M
    RARE annual total current liabilities is $344.15 million

    Accounts payable

    $38.76M
    RARE annual accounts payable is $38.76 million

    Debt

    Total debt

    $910.01M
    RARE annual total debt is $910.01 million

    Total debt 1-year change

    -2.65%
    RARE annual total debt is down -2.65% year-on-year

    Long term debt

    $849.87M
    RARE annual long term debt is $849.87 million

    Short term debt

    $60.14M
    RARE annual short term debt is $60.14 million

    Equity & Capital

    Shareholders equity

    $255.30M
    RARE annual stockholders equity is $255.30 million

    Book value

    $255.30M
    RARE annual book value is $255.30 million

    Retained earnings

    -$3.96B
    RARE annual retained earnings is -$3.96 billion

    Working capital

    $472.97M
    RARE annual working capital is $472.97 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    -$414.19M
    RARE annual cash flow from operations is -$414.19 million

    Cash from operations 1-year change

    +12.77%
    RARE annual cash flow from operations is up +12.77% year-on-year

    Cash from investing

    -$17.77M
    RARE annual cash flow from investing activities is -$17.77 million

    Cash from investing 1-year change

    -110.58%
    RARE annual cash flow from investing activities is down -110.58% year-on-year

    Cash from financing

    $399.24M
    RARE annual cash flow from financing activities is $399.24 million

    Cash from financing 1-year change

    +2.86%
    RARE annual cash flow from financing activities is up +2.86% year-on-year

    CAPEX

    CAPEX

    $19.99M
    RARE annual capital expenditures is $19.99 million

    CAPEX 1-year change

    -57.25%
    RARE annual capital expenditures is down -57.25% year-on-year

    Free Cash Flow

    Free cash flow

    -$434.18M
    RARE annual free cash flow is -$434.18 million

    Free cash flow 1-year change

    +16.76%
    RARE annual free cash flow is up +16.76% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    80.94%
    RARE annual gross profit margin is 80.94%

    Operating margin

    -95.67%
    RARE annual operating profit margin is -95.67%

    Net margin

    -101.60%
    RARE annual net profit margin is -101.60%

    ROA & ROE

    ROA

    -37.94%
    RARE annual return on assets is -37.94%

    ROE

    -211.71%
    RARE annual return on equity is -211.71%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    -
    RARE price to earnings ratio value is unknown

    PE ratio Sector rank

    -
    RARE price to earnings ratio is unknown

    PB Ratio

    PB ratio

    18.47
    RARE price to book ratio is 18.47

    PB ratio Sector rank

    94.28%
    RARE price to book ratio is higher than 94.28% of companies in Healthcare sector

    PS Ratio

    PS ratio

    4.58
    RARE price to sales ratio is 4.58

    PS ratio Sector rank

    55.57%
    RARE price to sales ratio is higher than 55.57% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $3.18B
    RARE enterprise value is $3.18 billion

    Enterprise value Sector rank

    85.12%
    RARE enterprise value is higher than 85.12% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -6.77
    RARE EV/EBITDA is -6.77

    EV/EBITDA Sector rank

    18.64%
    RARE EV/EBITDA is higher than 18.64% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    2.37
    RARE annual current ratio is 2.37

    Quick ratio

    2.03
    RARE annual quick ratio is 2.03

    Leverage

    Debt to equity

    3.56
    RARE annual debt to equity ratio is 3.56

    Interest coverage ratio

    -
    RARE annual interest coverage ratio value is unknown

    Risk & Stability

    Piotroski F-Score

    4
    RARE piotroski f-score is 4

    Altman Z-Score

    -2.69
    RARE altman z-score is -2.69

    Analyst ratings

    Recent major analysts updates

    Oct 22, 24 Cantor Fitzgerald
    Overweight
    Oct 21, 24 TD Cowen
    Buy
    Oct 1, 24 Cantor Fitzgerald
    Overweight
    Sep 26, 24 RBC Capital
    Outperform
    Sep 20, 24 Cantor Fitzgerald
    Overweight
    Sep 16, 24 Cantor Fitzgerald
    Overweight
    Aug 5, 24 Barclays
    Overweight
    Aug 2, 24 Wells Fargo
    Overweight
    Aug 2, 24 Wedbush
    Neutral
    Aug 2, 24 Goldman Sachs
    Buy

    Institutional Ownership

    Screeners with RARE included

    Growing Shares Outstanding
    Mid cap stocks
    US stocks
    Stocks below SMA 200
    Most recommended stocks
    NASDAQ Dividend Calendar
    Stocks below analysts price target
    Healthcare sector
    All stocks
    NASDAQ Listed Companies
    • What is the ticker symbol for Ultragenyx Pharmaceutical Inc.?
    • Does Ultragenyx Pharmaceutical Inc. pay dividends?
    • What sector is Ultragenyx Pharmaceutical Inc. in?
    • What industry is Ultragenyx Pharmaceutical Inc. in?
    • What country is Ultragenyx Pharmaceutical Inc. based in?
    • When did Ultragenyx Pharmaceutical Inc. go public?
    • Is Ultragenyx Pharmaceutical Inc. in the S&P 500?
    • Is Ultragenyx Pharmaceutical Inc. in the NASDAQ 100?
    • Is Ultragenyx Pharmaceutical Inc. in the Dow Jones?
    • When was Ultragenyx Pharmaceutical Inc.'s last earnings report?
    • When does Ultragenyx Pharmaceutical Inc. report earnings?

    What is the ticker symbol for Ultragenyx Pharmaceutical Inc.?

    The ticker symbol for Ultragenyx Pharmaceutical Inc. is NASDAQ:RARE

    Does Ultragenyx Pharmaceutical Inc. pay dividends?

    No, Ultragenyx Pharmaceutical Inc. does not pay dividends

    What sector is Ultragenyx Pharmaceutical Inc. in?

    Ultragenyx Pharmaceutical Inc. is in the Healthcare sector

    What industry is Ultragenyx Pharmaceutical Inc. in?

    Ultragenyx Pharmaceutical Inc. is in the Biotechnology industry

    What country is Ultragenyx Pharmaceutical Inc. based in?

    Ultragenyx Pharmaceutical Inc. is headquartered in United States

    When did Ultragenyx Pharmaceutical Inc. go public?

    Ultragenyx Pharmaceutical Inc.'s initial public offering (IPO) was on January 31, 2014

    Is Ultragenyx Pharmaceutical Inc. in the S&P 500?

    No, Ultragenyx Pharmaceutical Inc. is not included in the S&P 500 index

    Is Ultragenyx Pharmaceutical Inc. in the NASDAQ 100?

    No, Ultragenyx Pharmaceutical Inc. is not included in the NASDAQ 100 index

    Is Ultragenyx Pharmaceutical Inc. in the Dow Jones?

    No, Ultragenyx Pharmaceutical Inc. is not included in the Dow Jones index

    When was Ultragenyx Pharmaceutical Inc.'s last earnings report?

    Ultragenyx Pharmaceutical Inc.'s most recent earnings report was on August 5, 2025

    When does Ultragenyx Pharmaceutical Inc. report earnings?

    The next expected earnings date for Ultragenyx Pharmaceutical Inc. is November 6, 2025
    On this page